Oxford Drug Design is pleased to announce the addition of Prof. David Livermore to our Scientific Advisory Board.
Oxford Drug Design is pleased to announce the appointment of James B. Kahn, M.D. FIDSA, to the company’s Scientific Advisory Board.
InhibOx announces a change of name to Oxford Drug Design to reflect its transition to biotechnology company focussed on internal drug discovery.
Oxford Drug DesignOxford Centre for InnovationNew RoadOxfordOX1 1BY
Phone: +44 (0) 1865 261 468